| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 380.7 | 91.2 | 290.3 | 331.5 |
| Depreciation and amortization | 40.9 | 42.7 | 39.2 | 38.1 |
| Non-cash operating lease cost | 6.5 | 6.6 | 6.8 | 6.4 |
| Stock-based compensation (note 10) | 45.4 | 39.2 | 41.2 | 37.5 |
| Gain on sale of product groups (note 5) | NaN | 33.9 | 0 | NaN |
| Intangible assets impairment charges | NaN | NaN | 40 | NaN |
| Change in fair value of contingent consideration liabilities (note 13) | NaN | 0 | -12.5 | NaN |
| Loss on investments, net | -3.5 | NaN | NaN | NaN |
| Deferred income taxes | -9.4 | 54.4 | 18 | 20.9 |
| Gain on remeasurement of previously held interest upon acquisition (note 7) | 65.2 | 0 | 0 | NaN |
| Loss on impairment | NaN | NaN | 47.1 | NaN |
| Loss on impairment (note 6) | 123.6 | 139.8 | NaN | 47.1 |
| Other Noncash Income Expense | -0.5 | -5.4 | 6 | -4.7 |
| Accounts and other receivables, net | 117.9 | -32.4 | -13.2 | 24.9 |
| Inventories | 1.6 | -11 | 1.8 | -41.6 |
| Accounts payable and accrued liabilities | -347.1 | 168.7 | 226.1 | 103.7 |
| Income taxes | 41.9 | 57.6 | -10.2 | -240.4 |
| Prepaid expenses and other current assets | 8.7 | 6.2 | 14.2 | 13.9 |
| Long-term prepaid royalties (note 3) | NaN | -8.3 | NaN | NaN |
| Intellectual property agreement accrual | -50 | -14.8 | -12.5 | -12.5 |
| Increase Decrease In Other Operating Capital Net | 18.1 | 2.7 | 7.9 | -4.7 |
| Net cash provided by operating activities | 43.8 | 450.9 | 573.7 | 290.2 |
| Capital expenditures | 64.9 | 97.4 | 57.5 | 49.3 |
| Investments in unconsolidated affiliates | 6.3 | 15 | 1.5 | 48.3 |
| Purchases of held-to-maturity investments (note 5) | 12.5 | 0.1 | 24.4 | 6 |
| Proceeds from held-to-maturity investments (note 5) | 12.5 | 7.9 | 22.2 | 14.3 |
| Purchases of available-for-sale investments (note 5) | 641.1 | 826.6 | 1,006.4 | 624.3 |
| Proceeds from available-for-sale investments (note 5) | 710.1 | 706.6 | 669.7 | 611.8 |
| Investments in intangible assets | NaN | 0 | 0 | 0 |
| Payment for working capital adjustment and sale of product group (note 4) | 0 | 0 | 0 | 0 |
| Business combinations, net of cash (note 7) | 35.1 | 0 | 0 | NaN |
| Payment for acquisition options | 0 | 5.5 | 2.6 | 14 |
| Proceeds from sale of non-core product group (note 5) | NaN | 78.8 | NaN | NaN |
| Issuances of notes receivable | 55.2 | 47.5 | 22.8 | 52.8 |
| Other | 0.3 | -0.5 | 4.5 | 3.5 |
| Net cash (used in) provided by investing activities | -92.8 | -198.3 | -427.8 | -172.1 |
| Purchase of remaining noncontrolling interest in subsidiary (note 9) | NaN | 0 | 233.7 | NaN |
| Purchases of treasury stock | 421.8 | 40.6 | 588.7 | 5.5 |
| Equity forward contract related to accelerated share repurchase agreement (note 11) | 50 | NaN | 50 | 0 |
| Proceeds from stock plans | 68.9 | 32.3 | 34.7 | 57.2 |
| Other | 1.7 | -3.1 | -2.4 | 1 |
| Net cash used in financing activities | -451.2 | -11.4 | -740.1 | 52.7 |
| Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash | 8.2 | 3.5 | -1 | -29.6 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -492 | 244.7 | -595.2 | 141.2 |
| Cash, cash equivalents, and restricted cash at beginning of period | 2,939.5 | 2,694.8 | 3,290 | 3,148.8 |
| Cash, cash equivalents, and restricted cash at end of period (note 2) | 2,447.5 | 2,939.5 | 2,694.8 | 3,290 |
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW)